Compare Royal Bank of Canada (RY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs BIO-TECHNE Corp — how do they compare? Royal Bank of Canada trades at $210.91 (market cap $289.51B), while BIO-TECHNE Corp trades at $71.8 (market cap $11.16B). The key difference: Royal Bank of Canada is far larger — about 25.9× BIO-TECHNE Corp's market cap, and Royal Bank of Canada pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| RY | TECH | |
|---|---|---|
Market Cap | $289.51B | $11.16B |
Sector | Financials | Health |
52-Week High | $217.87 | $72.12 |
52-Week Low | $128.46 | $43.31 |
Dividend Yield | 2.42% | 0.45% |
Enterprise Value | — | $11.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $210.37, down 2.35% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent financial performance includes robust revenue growth to $66.53B in 2025 and a healthy net income margin of 31.85%, while the company maintains a solid dividend program with recent increases.
RY presents a mixed outlook with strong fundamentals and analyst support but faces valuation concerns. The company's consistent earnings beats and shareholder returns through dividends and buybacks provide upside potential, though elevated P/E and P/S ratios warrant caution. Key risks include economic sensitivity and competitive pressures in the banking sector.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
